Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 7395
Sealed predictions
- G3BP2 in dopamine neurons, braak+0.11 (p 0.785) → -0.02 (p 0.959)receipt 7403
Swarm cases
receipt 7403: G3BP2 in dopamine neurons, braak
- power
- full sample -0.19 (p 0.450, n 18), 95% CI -0.60 to +0.30. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.32 (p 0.194, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.29 (p 0.250, n 18). could be the mix.
- skeptic
- leave-one-out range -0.33 to -0.09, sign flips 0; without severely affected donors -0.19 (p 0.450, n 18). fragile.
- cell type
- strongest in astrocytes: -0.59 (p 0.0096, n 18) vs -0.19 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for G3BP2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up G3BP2 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.02 p 0.929 (needs p < 2.8e-4)
Receipts
loading the receipts